🔴 Telix Pharmaceuticals is trading 4.37% down today despite broad U.S. market gains

Telix Pharmaceuticals is trading 4.37% down at $11.38 on September 11, 2026, despite broad U.S. market gains; the precise catalyst remains unclear.

• The key near-term catalyst is the FDA’s September 11 PDUFA target date for Pixclara, its glioma-imaging agent.
• No confirmed FDA decision or new company announcement explaining the decline was found.
• The divergence from rising major indexes suggests company-specific trading pressure.